Drug Trial Radar · NCT04889430
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Jan 17, 2022
Primary completion
Apr 11, 2026
Study completion Apr 11, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Conditions
- Atypical Hemolytic Uremic Syndrome
Interventions
IptacopanDrug
Iptacopan 200mg twice daily oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with complete TMA response without the use of PE/PI and anti-C5 antibodyTime frame: 26 weeks of study treatment
- Long term safety and efficacy evaluationsTime frame: 52 weeks of study treatment
Locations
36 sites in 8 countries. Site status is shown where the registry gives one.
USC Norris Cancer Center
Los Angeles, California
Univ of California at Los Angeles
Los Angeles, California
Univ Cali Irvine ALS Neuromuscular
Orange, California
Univ of California at Sacramento
Sacramento, California
Harbor-UCLA Medical Center .
Torrance, California
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia
University Of Miami
Miami, Florida
University of Minnesota
Minneapolis, Minnesota
Montefiore Medical Center .
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Comprehensive Transplant Ctr at OSU
Columbus, Ohio
UT Southwestern Medical Center
Dallas, Texas
Virginia Commonwealth University
Richmond, Virginia
Novartis Investigative Site
Rio de Janeiro, Brazil
Novartis Investigative Site
Salvador, Brazil
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Brasília, Federal District, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site
Recife, Pernambuco, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Ostrava, Poruba, Czechia
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
Chandigarh, Punjab, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, India
Novartis Investigative Site
Iruma-gun, Saitama, Japan
Novartis Investigative Site
Seoul, Seoul, South Korea
Novartis Investigative Site
Taichung, Taiwan
Novartis Investigative Site
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.